[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370380-105":59,"doc-detail-370380-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-protease-cleavable-liposome-for-codelivery-of-anti-pd-l1-and-doxorubicin-for-colon-cancer-therapy-in-mice","A protease-cleavable liposome for codelivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice","","Immune checkpoint blockade with PD1/PD-L1 benefits advanced cancers, yet only a minority of colon cancer patients respond. A protease-cleavable anti-PD-L1 antibody liposome (eLipo anti-PD-L1) was engineered to be cleaved by legumain at the tumor site, generating pegylated anti-PD-L1 and a cancer-homing doxorubicin liposome. Functional studies show cancer-targeting, legumain-responsiveness, tumor penetration, immune activation, and in vivo efficacy in colon cancer-bearing mice. Mechanistic analysis links T cell differentiation and TCR signaling genes, and human tissue evaluations confirm PD-L1 and legumain expression.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-protease-cleavable-liposome-for-codelivery-of-anti-pd-l1-and-doxorubicin-for-colon-cancer-therapy-in-mice/370380/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-protease-cleavable-liposome-for-codelivery-of-anti-pd-l1-and-doxorubicin-for-colon-cancer-therapy-in-mice/370380.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is eLipo anti-PD-L1 designed to do in colon cancer therapy?","Question",{"text":113,"@type":114},"eLipo anti-PD-L1 is a protease-cleavable liposome engineered to improve colon cancer treatment by locally processing at the tumor site and enabling targeted delivery of immunotherapy components.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does legumain contribute to the liposome’s tumor-site activation?",{"text":118,"@type":114},"In vivo, eLipo anti-PD-L1 is cleaved by legumain at the colon cancer site into pegylated anti-PD-L1 and a cancer-homing doxorubicin liposome.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports immune activation and therapeutic efficacy?",{"text":122,"@type":114},"Functional assessments demonstrate cancer-targeting, legumain-responding, tumor-penetrating, and immune-activating effects, along with therapeutic efficacy in colon cancer-bearing mice. Mechanistic analysis implicates genes related to T cell differentiation and T cell receptor signaling.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370380,1790698002,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Article [https://doi.org/10.1038/s41467-025-57965-6](https://doi.org/10.1038/s41467-025-57965-6)  \nA protease-cleavable liposome for codelivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice  \nReceived: 24 June 2023  \n\n| Accepted: 7 March 2025 |\n| --- |\n| |\n| Check for updates |\n\nYixuan Liu1,2,3, Ying Xie1,2,3, Yuling Chen1,2, Jialun Duan1,2, Chunjie Bao1,2, Jinling Wang1,2, Hexuan Feng1,2, Mengjie Wang1,2, Yuxin Ren1,2, Peishan Li1,2, Qian Luo1,2, Jiarui Xu1,2, Min Jiang1,2, Yanchen Men1,2, Yang Wu1,2, Jianwei Li1,2, Guiling Wang1,2 & Wanliang Lu 1,2   \nImmune checkpoint blockade therapy using programmed cell death 1 (PD1) or programmed death ligand 1 (PD-L1) has made signiﬁcant progress in the treatment of advanced cancers, with some patients achieving long-term remission without clinical recurrence. However, only a minority of colon cancer patients respond to the therapy. Here, we report a protease-cleavable anti-PD-L1 antibody liposome, eLipo anti-PD-L1, for enhancing colon cancer therapy. In vivo, eLipo anti-PD-L1 is cleaved by legumain at colon cancer site into pegylated anti-PD-L1 and cancer-homing doxorubicin liposome. Functional assessments show cancer-targeting, legumain-responding, tumorpenetrating, and immune-activating effects, as well as efﬁcacy in treating colon cancer-bearing mice in vivo. Further mechanistic analysis implicates genes related to T cell differentiation and T cell receptor signaling as potential molecular mediators. Lastly, human colorectal cancer tissue evaluations verify expressions of PD-L1 and legumain, hinting a potential translatability. Our study thus suggests that eLipo anti-PD-L1 may be a feasible vector for codelivery of immunochemotherapy for colon cancer.  \nColon cancer is a cancer that develops from the colon part of the large intestine. It is also called bowel cancer or colorectal cancer because the anterior end of the colon is connected to the cecum and the posterior end to the rectum, forming the large intestine1. Treatment strategies for colorectal cancer mainly consist of surgery, radiation therapy, chemotherapy etc. Colon cancer that is conﬁned within the colon maybe curable with surgery, but usually cannot be cured when it has spread widely2. The survival depends on how advanced the cancer is, whether all the cancer can be excised with surgery or not, and the patient’s health status3. Survival of the patient is directly related to detection and the type of cancer involved, but overall prognosis is poor for the advanced. In developed countries, the ﬁve-year survival rate for colorectal cancer is only about a third of patients4,5.  \nImmune checkpoint blockade therapy using programmed death 1 (PD1) or programmed cell death ligand 1 (PD-L1) has made signiﬁcant progress in the treatment of advanced malignancies, with some patients achieving long-term remission without clinical recurrence6–13. Evidence shows that PD-L1 is expressed at 89% in colorectal tumor tissues and 5% in normal human tissue cells14, and the speciﬁc rich expression of PD-L1 in colorectal cancer provides a particular advantage for immune checkpoint blockade therapy. Immune checkpoint inhibitors(ICIs) like PD1antibodies pembrolizumab15, nivolumab16, and dostarlimab17 have been used as ﬁrst-line therapy for metastatic colorectal cancer (CRC) with defective mismatch repair (dMMR) and/or high microsatellite instability (MSI-H). The results demonstrate that the patients are highly sensitive to these inhibitors (ICIs), leading to  \n1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 100191 Beijing, China. 2Beijing Key Laboratory of Molecular Pharmaceutics and Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, 100191 Beijing, China. 3These authors contributed equally: Yixuan Liu, Ying Xie e-mail: [luwl@bjmu.edu.cn](luwl@bjmu.edu.cn)  \nsigniﬁcantly longer progression-free survival as compared to chemotherapy. Besides, there","cbCaivOd4BZoLA8x","https://ap.wps.com/l/cbCaivOd4BZoLA8x","pdf",5795332,22,"English","# Background\n## Colon cancer and treatment challenges\n## PD1/PD-L1 checkpoint blockade and limited responses\n# Strategy and Design\n## eLipo anti-PD-L1 protease-cleavable concept\n## Tumor-targeting and doxorubicin codelivery\n# Preclinical Findings\n## Cancer targeting, legumain response, and tumor penetration\n## Immune activation and therapeutic efficacy in mice\n# Mechanism and Translational Potential\n## T cell differentiation and TCR signaling mediators\n## Human tissue expression validation","[{\"question\":\"What is eLipo anti-PD-L1 designed to do in colon cancer therapy?\",\"answer\":\"eLipo anti-PD-L1 is a protease-cleavable liposome engineered to improve colon cancer treatment by locally processing at the tumor site and enabling targeted delivery of immunotherapy components.\"},{\"question\":\"How does legumain contribute to the liposome’s tumor-site activation?\",\"answer\":\"In vivo, eLipo anti-PD-L1 is cleaved by legumain at the colon cancer site into pegylated anti-PD-L1 and a cancer-homing doxorubicin liposome.\"},{\"question\":\"What evidence supports immune activation and therapeutic efficacy?\",\"answer\":\"Functional assessments demonstrate cancer-targeting, legumain-responding, tumor-penetrating, and immune-activating effects, along with therapeutic efficacy in colon cancer-bearing mice. Mechanistic analysis implicates genes related to T cell differentiation and T cell receptor signaling.\"}]","A protease-cleavable liposome for codelivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice | PDF",1790188244,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c373f4f4bdf3ee4aac5ed82d703d896.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cfeab9bdce73b8c9b39a14dec6dbbeb.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e924b6fa1f3f28cd0acc3a3ad3bb7076.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd03663c501548978b5af67b631d8704.webp",980,1301]